



17th November 2023

To,
The Secretary,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400 001
Scrip Code: 500674

The Secretary,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra East,
Mumbai 400 050
Symbol: SANOFI

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI (LODR) Regulations").

Dear Sir/Madam,

This is with reference to our earlier communication dated 11th November 2023, informing about the order dated 9th November 2023 passed by the Hon'ble NCLT, Mumbai Bench ("**Order**") directing convening of meeting of the equity shareholders and unsecured creditors of Sanofi India Limited ("**Company/ Demerged Company**") on 18th December 2023, to approve the scheme of arrangement for demerger of the consumer healthcare business of the Demerged Company into its wholly owned subsidiary, Sanofi Consumer Healthcare India Limited ("**Resulting Company**") under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("**Scheme**").

The appointed date as stipulated in the Order is 1st April 2023. In this regard, we would like to inform you that the Company and the Resulting Company has filed a joint application before the Hon'ble NCLT, Mumbai Bench, seeking rectification of an apparent error in the Order, in relation to the appointed date fixed by the Hon'ble NCLT, Mumbai Bench.

This is for your information and records.

Thanking you,

Yours faithfully

For **Sanofi India Limited**

Radhika Shah
Company Secretary & Compliance Officer